RxDoctor Payments Data

Greg Flaker, MD

Clinical Cardiac Electrophysiology · Columbia, MONPI 1851342299

Payments from drug & device makers

$3,670in general payments, 2019–2025

Across 53 payments — averaging $69.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Biosense Webster, Inc.$526
  • Abbott$205
  • Sanofi-aventis U.S. LLC$177
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$154
  • Johnson & Johnson$140
  • plus $383 from 7 others

What the payments were for

  • Travel & lodging$1,12631%
  • Food & beverage$2,54469%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,670 in reported general payments places this provider in the 15th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$57,627
Medicare patients
1,259
Services billed
1,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$264,066
EntrestoSacubitril/Valsartan95$106,809
Repatha SureclickEvolocumab71$76,470
FarxigaDapagliflozin Propanediol60$61,441
XareltoRivaroxaban21$21,863
Praluent PenAlirocumab12$14,250
VascepaIcosapent Ethyl11$3,792
Atorvastatin Calcium220$3,458
Metoprolol Succinate138$3,032
Eplerenone19$2,732
Verapamil SrVerapamil Hcl11$2,525
Flecainide Acetate45$2,455
Diltiazem 24hr Er (Cd)Diltiazem Hcl45$1,782
Amiodarone Hcl62$1,650
Spironolactone96$1,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$34$106,80995 claims
Johnson & JohnsonXarelto$140$21,86321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →